(Q40547936)

21 September 2017

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors (English)

1 reference

21 September 2017

5

1 reference

21 September 2017

Francesca Carlomagno

1

1 reference

21 September 2017

Teresa Guida

2

1 reference

21 September 2017

Suresh Anaganti

3

1 reference

21 September 2017

Giancarlo Vecchio

4

1 reference

21 September 2017

Anderson J Ryan

6

1 reference

21 September 2017

Marc Billaud

7

1 reference

21 September 2017

Massimo Santoro

8

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

21 September 2017

1 reference

21 September 2017

23

1 reference

21 September 2017

6056-6063

1 reference

21 September 2017

36

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207810

21 September 2017

0 references

cites work

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

A RET double mutation in the germline of a kindred with FMTC.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

A chemical switch for inhibitor-sensitive alleles of any protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Management of malignant gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Early Malignant Progression of Hereditary Medullary Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

The RET receptor: function in development and dysfunction in congenital malformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

1 reference

7 January 2021

Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Receptor tyrosine kinases as targets for anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207810

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1207810

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference